BioMarin Pharmaceuticals Inc BMRN
$54.62
-0.49%
at last close
Market Cap$10.63 billion
P/E Ratio—
Div Yield—
Volume467.9K
52-Week Range
$49.26$70.98
Analyst Ratings
- Consensus
- Buy — 15 Buy · 5 Hold · 0 Sell (20 analysts)
- Avg. Price Target
- $88.75 (+62.5% upside)
Key Stats
- Today's Range
- $54.48 – $55.98
- 50-Day Range
- $53.90 – $70.98
- 52-Week Range
- $49.26 – $70.98
- Volume
- 468K shs
- Average Volume
- 2.05 million shs
- Market Cap
- $10.63 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 4.98%
- Days to Cover
- 11.50
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Related Stocks
Compare head-to-head: BMRN vs LLY·BMRN vs JNJ·BMRN vs ABBV·BMRN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.